How to access Daybue from India, the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
An Indian family of a child, adolescent, or adult with Rett syndrome may receive a prescription for Daybue (trofinetide) from their treating paediatric neurologist. Daybue is FDA-approved as the first therapy specifically indicated for Rett syndrome, developed by Acadia Pharmaceuticals. Rett syndrome is a rare, progressive, X-linked neurodevelopmental disorder affecting primarily girls, with onset typically in early childhood. In India, Daybue may not be registered with CDSCO (we confirm its current CDSCO status for your case at intake), which is why your paediatric neurologist will navigate the Central Drugs Standard Control Organisation (CDSCO) named-patient / personal-import pathway on your behalf.
This guide explains the legal pathway, what documentation your physician needs, typical timing and how quotes work, and where Reserve Meds fits in.
Ask about Daybue in India
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
The clinical situation
Daybue is a synthetic analogue of a naturally occurring tripeptide derived from insulin-like growth factor 1 (IGF-1), taken as an oral liquid twice daily dosed by weight. Eligibility is based on clinical diagnosis of Rett syndrome, typically supported by genetic confirmation of a pathogenic variant in MECP2, and ongoing management by a paediatric neurologist familiar with Rett syndrome. Your neurologist will confirm diagnosis, baseline function (using standardised Rett-specific scales), and set up monitoring. Daybue can cause diarrhoea and vomiting, so families are counselled on hydration and dose-adjustment strategies. Because Daybue is oral, in-country administration is straightforward once the prescribing plan is in place.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
Is Daybue legally importable into India?
Yes, through the CDSCO named-patient import framework and the personal-use import allowance under the Drugs and Cosmetics Rules.
The pathway permits import of a medicine not locally registered when: (a) the medicine is approved by a recognised reference authority such as the US FDA, (b) no clinically equivalent locally registered alternative is available, (c) a treating physician takes clinical responsibility, and (d) the importing party documents chain of custody end to end. For Rett syndrome in India, there is no locally registered disease-specific alternative, making the clinical rationale direct.
How the pathway works, step by step
- Consultation with your treating paediatric neurologist. Clinical diagnosis of Rett syndrome with supporting MECP2 genetic confirmation, and a written clinical rationale.
- Baseline assessment. Weight, Rett-specific functional scales, GI tolerance baseline, and hydration plan are documented.
- CDSCO named-patient / personal-import application. Your physician or the hospital pharmacy files the application with clinical rationale, genetic report, patient reference, and chain-of-custody plan.
- US-side sourcing. Reserve Meds coordinates with our US-licensed pharmaceutical wholesale partner to secure Daybue from authorised distribution.
- Shipment. Daybue ships with chain-of-custody documentation; manufacturer handling conditions apply during transport.
- Arrival and dispensing. The hospital pharmacy releases the bottle to the family with weight-based dosing instructions and GI-symptom management guidance.
What documentation your physician needs
Your physician will typically need to provide:
- A clinical rationale letter confirming Rett syndrome diagnosis, MECP2 report, baseline function, and Daybue as the indicated treatment
- Verification of their Indian medical registration (NMC / state council)
- A copy of the MECP2 genetic diagnostic report
- Patient identifier (anonymised reference where possible)
- Planned dosing schedule based on weight, with a plan for dose adjustments as the child grows and for management of GI tolerability
Reserve Meds provides a physician documentation kit that bundles the templates CDSCO reviewers expect to see for rare-paediatric-neurology named-patient imports, including the GI-tolerability and hydration-management plan central to Daybue adherence.
Costs and timing
The cost of Daybue is weight-dependent because dosing scales with body weight. Medicine price: quote on request. You get a written quote for your case before you commit. International logistics, CDSCO documentation handling, and coordination add incremental cost. Reserve Meds issues a full transparent quote at the start of intake.
We give you a written timeline estimate for your case before you commit. Refills ship on a rolling basis against the monthly dispensing schedule.
If your clinical situation is time-sensitive, tell us at intake. We triage accordingly.
A culturally-aware note: India's rare-disease community has grown through patient-family advocacy networks, and Rett syndrome families are often connected through national Rett-specific groups. Caregiving is typically maternal-led, with extended family, grandparents, aunts, cousins, providing structured support. Our coordination recognises the multi-city caregiving pattern common in Indian families (genetic diagnosis in one metro, specialist follow-up in another) and provides a single case lead who coordinates refill logistics across locations.
Reserve Meds's role
Reserve Meds is a US-based digital health company that coordinates access to cross-border specialty medicine. For Daybue specifically, we provide:
- Sourcing. Through our US-licensed pharmaceutical wholesale partner, operating under DSCSA chain-of-custody.
- Documentation. Regulatory package for your physician and for CDSCO review.
- Logistics. Chain-of-custody shipment coordination to your prescribing hospital pharmacy.
- Dedicated case lead. A named point of contact for the family, coordinating long-term refills and weight-based dose adjustments as the child grows.
What we do not do: we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy. All clinical decisions remain with your treating paediatric neurologist.
Frequently asked
Is this legal in India? Yes, when executed through the CDSCO named-patient / personal-import framework with appropriate documentation. See our trust and compliance page.
Is Daybue a cure? No. Daybue is a disease-modifying therapy intended to improve certain Rett-syndrome symptoms. Pivotal study endpoints focused on functional improvement. Your paediatric neurologist will discuss realistic outcome expectations.
How is GI tolerability managed? Diarrhoea and vomiting are recognised on-label effects. Your neurology team will advise on dose adjustment strategies, hydration planning, and anti-diarrhoeal supportive measures.
Can an adult with Rett syndrome receive Daybue? Yes, FDA labelling covers paediatric and adult patients. Your physician will advise on age- and weight-appropriate dosing.
Will insurance cover this? Cash-pay is the default. Some private health insurers in India consider rare-disease imports on a case-by-case basis; we supply documentation for your submission but do not process insurance claims directly.
Recent regulatory and access news for Daybue in India
The CDSCO Notifications feed at cdsco.gov.in/Notifications has not posted a Daybue-specific notification over the last 12 months as of 2026-06-04. The Drugs Controller General of India has not added Daybue to the Approved New Drugs list at cdsco.gov.in Approved-New-Drugs. The National Pharmaceutical Pricing Authority database at nppaindia.nic.in and the Pharmacovigilance Programme of India at ipc.gov.in have not registered Daybue-specific signals. Acadia Pharmaceuticals continues commercial rollout of trofinetide for Rett syndrome in patients 2 years and older; this is the first FDA-approved Rett syndrome therapy. We update this section on each case file at intake; the snapshot date governs.
Next step
For Daybue coordination in India, start your case at the portal or message us on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.
Composite case examples. This content is for general information and does not constitute medical advice.
Reviewed by the Reserve Meds clinical operations team. Last reviewed: 2026-04-23.
Frequently asked questions
How can I get Daybue in India if it is not approved or available there?
Reserve Meds coordinates US-sourced Daybue for patients in India through a legal named-patient pathway, working with your treating doctor. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for India and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Daybue in India through a named-patient import?
Often, yes. Named-patient access (sometimes called personal import) is the legal route we use for FDA-approved medicines such as Daybue. It is different from compassionate use, which covers investigational medicines through the manufacturer's own program; we do not supply investigational medicines. Eligibility and paperwork depend on the regulator in India, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Daybue in India through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Daybue to a patient in India?
Medicines are supplied through a US-licensed pharmaceutical wholesale partner, and Reserve Meds coordinates delivery of Daybue to your treating physician or hospital pharmacy in India, with appropriate handling for the product.
How long does it take, and what does Daybue in India cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Daybue in India?
Submit a 60-second intake through the Reserve Meds patient portal, or message our team on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.